SAN FRANCISCO & GENEVA—Biotechnology company Amarantus Bioscience Holdings Inc. has initiated a master services agreement with ICON for global therapeutic and diagnostic clinical development services. To that end, Amarantus has submitted an initial work order to ICON to deliver the Fit for Purpose Flow Cytometry Assay Validation of the LymPro Test, an Alzheimer’s blood diagnostic, at ICON’s CLIA-certified laboratory. The agreement covers all of ICON’s laboratory sites globally.

 

“This agreement represents a major milestone for Amarantus, as we can now prepare LymPro for launch with a top-tier commercial development organization with the required CLIA capabilities as the backbone for launch in the United States and abroad,” stated Gerald E. Commissiong, president and CEO at Amarantus. “We are extremely pleased to be working with ICON, and we anticipate completion of the Fit for Purpose Flow Cytometry Assay Validation in the fourth quarter.”